Analysis of the relationship between risk score and the expression of crucial immune checkpoint genes revealed that high-risk patients had higher CTLA4, CD83, B3H7, OX40L, and GEM levels in the tumor microenvironment. This evidence concerns the gene CD83 and neoplasm.